Technical Mastery: Guidance on Proper Imaging, Lesion Preparation, and Deployment for Coronary Drug-Coated Balloons. Part 1: In-Stent Restenosis, Step-by-Step How to Treat-Welcome and CME Information, Coronary DCB Clinical Trials: Key Data and Their Implication for Practice , Dr. Sahil A. Parikh

Welcome and CME Information, Coronary DCB Clinical Trials: Key Data and Their Implication for Practice , Dr. Sahil A. Parikh

Back to course

Video Transcription

Video Summary

This Sky Interactive CME session, moderated by Sahil Preet, focused on the clinical application of coronary drug-coated balloons (DCBs), especially for in-stent restenosis (ISR). The program included discussions on technical mastery, imaging guidance, and lesion preparation for DCB deployment, with insights from experts including Evan Schlothmitz on intravascular imaging and Kate Kearney on clinical cases. The session highlighted key clinical trial data, particularly the Agent IDE study demonstrating the superiority of paclitaxel-coated balloons over plain balloon angioplasty in ISR treatment, showing durable benefits through two years, including lower target lesion failure, myocardial infarction, and stent thrombosis rates. The importance of drug choice, excipients, and drug delivery mechanics was emphasized. Current guidelines favor DCBs for ISR, with ongoing research into their use in de novo lesions, bifurcations, and high-bleeding risk patients. Experts discussed parallels with peripheral artery interventions and the need for robust RCTs. The evolving evidence base suggests DCBs offer significant clinical advantages without permanent implants.

Keywords

coronary drug-coated balloons

in-stent restenosis

intravascular imaging

Agent IDE study

paclitaxel-coated balloons

clinical trial data